14.30 - 15.00

Eröffnung

Begrüßung (M. Stöckle, Homburg/Saar)

Begrüßung (1. Vorsitzender des DPKK, N. Wernert, Bonn)

Einführung (G. Untergger, Homburg/Saar; C. Ohlmann, Homburg/Saar)

Moderation:

J. Kamradt

15.00 – 15.30

Personalized Therapies of Cancer – can we learn from successes in HIV therapy? (T. Lengauer, Saarbrücken)

15.30 – 16.15

Basic research in CRPC (W. Schulz, Düsseldorf)

16.15 – 16.45

Taxan resistance (P. Vrignaud, R&D Sanofi-Aventis France)

Moderation:

M. Janssen

17.15 – 17.45

Androgen resistance (B. Hadaschik, Heidelberg)

17.45 – 18.30

Epigenetic biomarkers in prostate cancer (J. Lewin, Epigenomics, Berlin)

18.30 – 19.00

Ziele der PREFERE-Studie (M. Stöckle, Homburg/Saar)

Diskussion

Moderation:

G. Unteregger

08.30 – 09.00

Treatment options in CRPC (C. Ohlmann, Homburg/Saar)

09.00 – 09.30

Biomarker in CRPC (G. Kristiansen, Bonn)

09.30 – 10.00

Most recent intervention strategies directed at the target androgen receptor: functional aspects (P. Thelen, Göttingen)

10.00 – 10.30

Drug modelling (M. Negri, Saarbrücken)

Moderation:

V. Jung

11.00 – 11.30

Tumor microenvironment: The Yin and Yang in cancer progression (L. Kunz- Schughart, Dresden)

11.30 – 12.00

Fibroblast – tumor cell interaction: A deathly crosstalk in CRPC? (G. Unteregger, Homburg/Saar)

Moderation:

C. Ohlmann

12.00 – 12.30

Bone targeted therapies (D. Schilling, Tübingen)

12.30 – 13.00

Bone targeted therapy: Nano-encapsulated ZOL (M. Caraglia, Naples)

13.00 - 13.15

Schlußworte (C. Ohlmann, Homburg/Saar; G. Unteregger, Homburg/Saar)